Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Klinman Website

Dennis M. Klinman, M.D.

Selected Publications
1)  Yasuda H, Leelahavanichkul A, Tsunoda S, Dear JW, Takahashi Y, Ito S, Hu X, Zhou H, Doi K, Childs R, Klinman DM, Yuen PS, Star RA.
Chloroquine and inhibition of Toll-like receptor 9 protect from sepsis-induced acute kidney injury.
Am. J. Physiol. Renal Physiol. 294: F1050-8, 2008. [Journal]
2)  Sato T, Shimosato T, Alvord WG, Klinman DM.
Suppressive oligodeoxynucleotides inhibit silica-induced pulmonary inflammation.
J. Immunol. 180: 7648-54, 2008. [Journal]
3)  Fogg CN, Americo JL, Lustig S, Huggins JW, Smith SK, Damon I, Resch W, Earl PL, Klinman DM, Moss B.
Adjuvant-enhanced antibody responses to recombinant proteins correlates with protection of mice and monkeys to orthopoxvirus challenges.
Vaccine. 25: 2787-99, 2007. [Journal]
4)  Saha S, Takeshita F, Matsuda T, Jounai N, Kobiyama K, Matsumoto T, Sasaki S, Yoshida A, Xin KQ, Klinman DM, Uematsu S, Ishii KJ, Akira S, Okuda K.
Blocking of the TLR5 activation domain hampers protective potential of flagellin DNA vaccine.
J. Immunol. 179: 1147-54, 2007. [Journal]
5)  Klaschik S, Gursel I, Klinman DM.
CpG-mediated changes in gene expression in murine spleen cells identified by microarray analysis.
Mol. Immunol. 44: 1095-104, 2007. [Journal]
6)  Shirota H, Petrenko L, Hong C, Klinman DM.
Potential of transfected muscle cells to contribute to DNA vaccine immunogenicity.
J. Immunol. 179: 329-36, 2007. [Journal]
7)  Klinman DM, Currie D, Lee G, Grippe V, Merkel T.
Systemic but not mucosal immunity induced by AVA prevents inhalational anthrax.
Microbes Infect. 9: 1478-83, 2007. [Journal]
8)  Shirota H, Ishii KJ, Takakuwa H, Klinman DM.
Contribution of interferon-beta to the immune activation induced by double-stranded DNA.
Immunology. 118: 302-10, 2006. [Journal]
9)  Klinman DM.
CpG oligonucleotides accelerate and boost the immune response elicited by AVA, the licensed anthrax vaccine.
Expert review of vaccines. 5: 365-9, 2006. [Journal]
10)  Klinman DM, Xie H, Ivins BE.
CpG oligonucleotides improve the protective immune response induced by the licensed anthrax vaccine.
Ann. N. Y. Acad. Sci. 1082: 137-50, 2006. [Journal]
11)  Gursel M, Gursel I, Mostowski HS, Klinman DM.
CXCL16 influences the nature and specificity of CpG-induced immune activation.
J. Immunol. 177: 1575-80, 2006. [Journal]
12)  Saha S, Takeshita F, Sasaki S, Matsuda T, Tanaka T, Tozuka M, Takase K, Matsumoto T, Okuda K, Ishii N, Yamaguchi K, Klinman DM, Xin KQ, Okuda K.
Multivalent DNA vaccine protects mice against pulmonary infection caused by Pseudomonas aeruginosa.
Vaccine. 24: 6240-9, 2006. [Journal]
13)  Fujimoto C, Yu CR, Shi G, Vistica BP, Wawrousek EF, Klinman DM, Chan CC, Egwuagu CE, Gery I.
Pertussis toxin is superior to TLR ligands in enhancing pathogenic autoimmunity, targeted at a neo-self antigen, by triggering robust expansion of Th1 cells and their cytokine production.
J. Immunol. 177: 6896-903, 2006. [Journal]
14)  Takeshita F, Tanaka T, Matsuda T, Tozuka M, Kobiyama K, Saha S, Matsui K, Ishii KJ, Coban C, Akira S, Ishii N, Suzuki K, Klinman DM, Okuda K, Sasaki S.
Toll-like receptor adaptor molecules enhance DNA-raised adaptive immune responses against influenza and tumors through activation of innate immunity.
J. Virol. 80: 6218-24, 2006. [Journal]
15)  Ito S, Ishii KJ, Ihata A, Klinman DM.
Contribution of nitric oxide to CpG-mediated protection against Listeria monocytogenes.
Infect. Immun. 73: 3803-5, 2005. [Journal]
16)  Xie H, Gursel I, Ivins BE, Singh M, O'Hagan DT, Ulmer JB, Klinman DM.
CpG oligodeoxynucleotides adsorbed onto polylactide-co-glycolide microparticles improve the immunogenicity and protective activity of the licensed anthrax vaccine.
Infect. Immun. 73: 828-33, 2005. [Journal]
17)  Ito S, Ishii KJ, Gursel M, Shirotra H, Ihata A, Klinman DM.
CpG oligodeoxynucleotides enhance neonatal resistance to Listeria infection.
J. Immunol. 174: 777-82, 2005. [Journal]
18)  Ito S, Pedras-Vasconcelos J, Klinman DM.
CpG oligodeoxynucleotides increase the susceptibility of normal mice to infection by Candida albicans.
Infect. Immun. 73: 6154-6, 2005. [Journal]
19)  Sugiyama T, Gursel M, Takeshita F, Coban C, Conover J, Kaisho T, Akira S, Klinman DM, Ishii KJ.
CpG RNA: identification of novel single-stranded RNA that stimulates human CD14+CD11c+ monocytes.
J. Immunol. 174: 2273-9, 2005. [Journal]
20)  Ishii KJ, Ito S, Tamura T, Hemmi H, Conover J, Ozato K, Akira S, Klinman DM.
CpG-activated Thy1.2+ dendritic cells protect against lethal Listeria monocytogenes infection.
Eur. J. Immunol. 35: 2397-405, 2005. [Journal]
21)  Coban C, Ishii KJ, Gursel M, Klinman DM, Kumar N.
Effect of plasmid backbone modification by different human CpG motifs on the immunogenicity of DNA vaccine vectors.
J. Leukoc. Biol. 78: 647-55, 2005. [Journal]
22)  Dalloul RA, Lillehoj HS, Klinman DM, Ding X, Min W, Heckert RA, Lillehoj EP.
In ovo administration of CpG oligodeoxynucleotides and the recombinant microneme protein MIC2 protects against Eimeria infections.
Vaccine. 23: 3108-13, 2005. [Journal]
23)  Xin KQ, Jounai N, Someya K, Honma K, Mizuguchi H, Naganawa S, Kitamura K, Hayakawa T, Saha S, Takeshita F, Okuda K, Honda M, Klinman DM, Okuda K.
Prime-boost vaccination with plasmid DNA and a chimeric adenovirus type 5 vector with type 35 fiber induces protective immunity against HIV.
Gene Ther. 12: 1769-77, 2005. [Journal]
24)  Dong L, Ito S, Ishii KJ, Klinman DM.
Suppressive oligodeoxynucleotides delay the onset of glomerulonephritis and prolong survival in lupus-prone NZB x NZW mice.
Arthritis Rheum. 52: 651-8, 2005. [Journal]
25)  Shirota H, Gursel I, Gursel M, Klinman DM.
Suppressive oligodeoxynucleotides protect mice from lethal endotoxic shock.
J. Immunol. 174: 4579-83, 2005. [Journal]
26)  Lugo-Villarino G, Ito S, Klinman DM, Glimcher LH.
The adjuvant activity of CpG DNA requires T-bet expression in dendritic cells.
Proc. Natl. Acad. Sci. U.S.A. 102: 13248-53, 2005. [Journal]
27)  Klinman DM, Gursel I, Klaschik S, Dong L, Currie D, Shirota H.
Therapeutic potential of oligonucleotides expressing immunosuppressive TTAGGG motifs.
Ann. N. Y. Acad. Sci. 1058: 87-95, 2005. [Journal]
28)  Takeshita F, Ishii KJ, Kobiyama K, Kojima Y, Coban C, Sasaki S, Ishii N, Klinman DM, Okuda K, Akira S, Suzuki K.
TRAF4 acts as a silencer in TLR-mediated signaling through the association with TRAF6 and TRIF.
Eur. J. Immunol. 35: 2477-85, 2005. [Journal]
29)  Klinman DM.
Adjuvant activity of CpG oligodeoxynucleotides.
Int. Rev. Immunol. 25: 135-54, , ,. [Journal]
30)  Sen G, Flora M, Chattopadhyay G, Klinman DM, Lees A, Mond JJ, Snapper CM.
The critical DNA flanking sequences of a CpG oligodeoxynucleotide, but not the 6 base CpG motif, can be replaced with RNA without quantitative or qualitative changes in Toll-like receptor 9-mediated activity.
Cell. Immunol. 232: 64-74, , ,. [Journal]
31)  Klinman D, inventor; DHHS, assignee.
Immune activation by double-stranded polynucleotides.
Patent Pending Application No. 09/151,612. Pending [Patent]
32)  Klinman D, inventor; DHHS, assignee.
Immunostimulatory RNA/DNA hybrid molecules.
Patent Pending, Filed in 2004. Application No. 2004-0052763-A1. Pending [Patent]
33)  Klinman D, inventor; DHHS, assignee.
Methods and products for treating HIV infection.
Patent Pending Application No. 09/931,583. Pending [Patent]
34)  Klinman D, inventor; DHHS, assignee.
Methods for treating and preventing infectious disease.
Patent Pending Application No. 10/187,489. Pending [Patent]
35)  Klinman D, inventor; DHHS, assignee.
Methods for treating and preventing infectious disease in non-human animals.
Patent Pending Application No. 09/629,477. Pending [Patent]
36)  Klinman D, inventor; DHHS, assignee.
Immunomostimulatory nucleic acid molecules.
US Patent: 6,207,646. 2001. [Patent]
37)  Klinman D, inventor; DHHS, assignee.
Oligodeoxynucleotide and its use to induce an immune response.
US Patent: 6,977,245. 2005. [Patent]

This page was last updated on 11/25/2008.